Core Viewpoint - Agios Pharmaceuticals, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws following disappointing results from its Phase 3 trial of Mitapivat in Sickle Cell Disease [1][2]. Group 1: Company Performance - On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial, which met one primary endpoint but failed to achieve a statistically significant improvement in the annualized rate of pain crises [2]. - The key secondary endpoint regarding change from baseline in PROMIS Fatigue was also not met, leading to a significant drop in Agios' stock price by $22.33, opening at $23.16 per share [2]. Group 2: Legal and Regulatory Actions - Levi & Korsinsky has initiated an investigation into Agios Pharmaceuticals concerning possible violations of federal securities laws, indicating potential legal challenges ahead for the company [1]. - The firm has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [3].

Core Viewpoint - Agios Pharmaceuticals, Inc. is under investigation for potential violations of federal securities laws following disappointing results from its Phase 3 trial of Mitapivat in Sickle Cell Disease, which led to a significant drop in stock price [1]. Group 1: Trial Results - On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial, which met one primary endpoint but failed to achieve a statistically significant improvement in the annualized rate of pain crises [1]. - The key secondary endpoint, change from baseline in PROMIS Fatigue, was also not met during the trial [1]. Group 2: Stock Market Reaction - Following the trial results, Agios' stock price fell by $22.33 per share, opening at $23.16 per share [1].

Core Viewpoint - Agios Pharmaceuticals, Inc. is under investigation for potential violations of federal securities laws following the mixed results of its RISE UP Phase 3 trial for Mitapivat in Sickle Cell Disease, which led to a significant drop in its stock price [1]. Group 1: Trial Results - On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial, which met one primary endpoint but failed to achieve a statistically significant improvement in the annualized rate of pain crises [1]. - The key secondary endpoint, which was the change from baseline in PROMIS Fatigue, was also not met [1]. Group 2: Stock Price Impact - Following the trial results, Agios' stock price fell by $22.33 per share, opening at $23.16 per share [1].

Group 1 - Agios Pharmaceuticals, Inc. (AGIO) stock has experienced a significant decline, down 49% and trading at $23 per share, resulting in a market capitalization of approximately $1.4 billion [1] - The article highlights the importance of staying updated on stocks within the biotech, pharma, and healthcare sectors, emphasizing key trends and catalysts that influence market valuations [1][2] Group 2 - The investing group Haggerston BioHealth, led by a biotech consultant with over 5 years of experience, provides insights and detailed reports on more than 1,000 companies in the biotech and healthcare sectors [2] - Haggerston BioHealth offers various resources for investors, including product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-by-market analysis [2]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]